文献速递慢性肾脏病

N-甲基-D-天冬氨酸受体抑制可减轻肥胖诱导的肾脏疾病

N-methyl-D-aspartate receptor inhibition protects against obesity-induced kidney disease.
PubMed 文献 · Nephrol Dial Transplant · 2026-01-01

本研究在肥胖诱导肾脏病(OIKD)小鼠模型、体外脂质超载模型及CKD患者肾活检中评估NMDAR表达,并通过药物抑制与过表达/敲低实验探讨其作用。结果显示FFA和高脂饮食上调GluN1,伴脂质蓄积和炎症;NMDAR拮抗减轻上述损伤,提示靶向NMDAR具治疗潜力。

要点

  • 肥胖诱导肾脏病中肾NMDAR(GluN1)表达升高。
  • NMDAR拮抗减轻脂质蓄积、炎症和肾小管损伤。
  • GluN1过表达促进炎症和p38活化,p38抑制剂可反馈抑制GluN1。

核心结论

  • 肾脏NMDAR参与肥胖诱导肾脏病的发病机制。
  • 靶向NMDAR可减轻肥胖相关肾病中的炎症和肾损伤,具治疗潜力。

研究设计与样本

  • 研究采用OIKD小鼠模型、体外脂质超载模型和CKD患者肾活检。
  • 结合药理学抑制(美金刚、MK-801)与HK-2细胞中NMDAR过表达和下调的功能获得/缺失策略。

主要发现

  • FFA暴露的HK-2细胞和高脂饮食小鼠模型中GluN1升高,伴脂质蓄积和炎症反应。
  • CKD患者肾活检显示GluN1水平升高。
  • 体外NMDAR拮抗减轻FFA诱导的脂质蓄积和炎症,调节氧化还原稳态并抑制p38磷酸化。
  • GluN1过表达增加炎症标志物、改变氧化还原调节因子并促进p38活化;p38抑制剂减少FFA诱导的GluN1上调并减轻炎症。
  • 体内NMDAR阻断减少高脂饮食驱动的炎症和肾小管损伤,并增强抗氧化基因表达。

临床怎么用

  • 提示NMDAR(GluN1)可能作为肥胖相关肾病的潜在干预靶点。
  • NMDAR拮抗(如美金刚、MK-801)在实验模型中减轻炎症和肾小管损伤,但临床转化需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Obesity-associated nephropathy is becoming increasingly prevalent, yet the molecular mechanisms linking metabolic stress to renal dysfunction remain unclear. N-methyl-D-aspartate receptors (NMDARs) are expressed in the kidney and are involved in the pathogenesis of different renal diseases. This study aimed to explore the role of NMDAR in obesity-induced kidney disease (OIKD). METHODS: NMDAR expression was assessed in a murine model of OIKD, an in vitro fat-overload model, and in kidney biopsies from chronic kidney disease (CKD) patients. We combined pharmacological inhibition with gain- and loss-of-function strategies: NMDAR antagonists, memantine and MK-801, were tested in vitro and in vivo, while NMDAR was overexpressed and downregulated in cultured proximal tubular epithelial (HK-2) cells to evaluate its contribution to OIKD. RESULTS: Free fatty acids (FFAs) exposure in HK-2 cells and high-fat diet (HFD) feeding in an OIKD mouse model led to increased GluN1, an essential subunit of NMDAR, accompanied by lipid accumulation and inflammatory responses associated with cellular injury. Kidney biopsies from CKD patients showed elevated GluN1 levels. In vitro, NMDAR antagonism attenuated FFA-induced cellular lipid accumulation and inflammation, regulated cellular redox homeostasis and suppressed FFA-induced p38 phosphorylation. GluN1 overexpression in HK-2 increased inflammatory markers, altered redox-regulating factors and promoted p38 activation. Treatment of cells with the p38 kinase inhibitor reduced FFA-induced GluN1 upregulation and attenuated inflammation. In vivo, NMDAR blockade reduced HFD-driven inflammation and tubular injury, and enhanced antioxidant gene expression. CONCLUSION: Our results demonstrate that renal NMDAR contributes to the pathogenesis of OIKD and underscore the therapeutic potential of targeting this receptor to attenuate inflammation and kidney injury in obesity-associated nephropathy.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Eritja À, Pérez-Olives C, Falcón DAR, et al. N-methyl-D-aspartate receptor inhibition protects against obesity-induced kidney disease. Nephrol Dial Transplant. 2026. PMID: 41671168. doi:10.1093/ndt/gfag027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。